In which adults is Wegovy (semaglutide) indicated to reduce major cardiovascular events?

Wegovy (semaglutide) is indicated alongside a reduced-calorie diet and increased physical activity to reduce cardiovascular death, non-fatal myocardial infarction or non-fatal stroke in adults with established cardiovascular disease and obesity or overweight (BMI at least 27 kg/m²).